"Physicians often can choose among several drugs to treat a patient,

... and the current Medicare Part B drug payment methodology can penalize doctors for selecting lower-cost drugs, even when these drugs are as good or better for patients based on the evidence."

— CMS noted upon its release this spring of a value-based Medicare drug plan, which was roundly criticized by virtually all stakeholders.